share_log

Is Dian Diagnostics GroupLtd (SZSE:300244) A Risky Investment?

Dian Diagnostics GroupLtd(SZSE:300244)はリスキーな投資ですか?

Simply Wall St ·  09/20 19:18

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. As with many other companies Dian Diagnostics Group Co.,Ltd. (SZSE:300244) makes use of debt. But should shareholders be worried about its use of debt?

When Is Debt A Problem?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. The first step when considering a company's debt levels is to consider its cash and debt together.

What Is Dian Diagnostics GroupLtd's Debt?

You can click the graphic below for the historical numbers, but it shows that Dian Diagnostics GroupLtd had CN¥3.75b of debt in June 2024, down from CN¥4.76b, one year before. However, it does have CN¥2.18b in cash offsetting this, leading to net debt of about CN¥1.57b.

big
SZSE:300244 Debt to Equity History September 20th 2024

How Healthy Is Dian Diagnostics GroupLtd's Balance Sheet?

Zooming in on the latest balance sheet data, we can see that Dian Diagnostics GroupLtd had liabilities of CN¥5.04b due within 12 months and liabilities of CN¥2.68b due beyond that. On the other hand, it had cash of CN¥2.18b and CN¥8.95b worth of receivables due within a year. So it can boast CN¥3.41b more liquid assets than total liabilities.

This surplus liquidity suggests that Dian Diagnostics GroupLtd's balance sheet could take a hit just as well as Homer Simpson's head can take a punch. On this view, lenders should feel as safe as the beloved of a black-belt karate master.

In order to size up a company's debt relative to its earnings, we calculate its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and its earnings before interest and tax (EBIT) divided by its interest expense (its interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio).

While Dian Diagnostics GroupLtd has a quite reasonable net debt to EBITDA multiple of 1.5, its interest cover seems weak, at 2.0. This does suggest the company is paying fairly high interest rates. In any case, it's safe to say the company has meaningful debt. Shareholders should be aware that Dian Diagnostics GroupLtd's EBIT was down 66% last year. If that earnings trend continues then paying off its debt will be about as easy as herding cats on to a roller coaster. There's no doubt that we learn most about debt from the balance sheet. But it is future earnings, more than anything, that will determine Dian Diagnostics GroupLtd's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

Finally, a business needs free cash flow to pay off debt; accounting profits just don't cut it. So it's worth checking how much of that EBIT is backed by free cash flow. Looking at the most recent three years, Dian Diagnostics GroupLtd recorded free cash flow of 38% of its EBIT, which is weaker than we'd expect. That's not great, when it comes to paying down debt.

Our View

We weren't impressed with Dian Diagnostics GroupLtd's interest cover, and its EBIT growth rate made us cautious. But like a ballerina ending on a perfect pirouette, it has not trouble staying on top of its total liabilities. We would also note that Healthcare industry companies like Dian Diagnostics GroupLtd commonly do use debt without problems. When we consider all the elements mentioned above, it seems to us that Dian Diagnostics GroupLtd is managing its debt quite well. Having said that, the load is sufficiently heavy that we would recommend any shareholders keep a close eye on it. There's no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet - far from it. For example - Dian Diagnostics GroupLtd has 1 warning sign we think you should be aware of.

Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする